Treatment of pre‐menopausal advanced breast cancer with goserelin—a long‐acting luteinizing hormone releasing hormone agonist

  title={Treatment of pre‐menopausal advanced breast cancer with goserelin—a long‐acting luteinizing hormone releasing hormone agonist},
  author={Cristina Brambilla and A. Escobedo and R Artioli and Mar{\'i}a Jos{\'e} Lechuga and Manuela Motta},
  journal={Anti-Cancer Drugs},
Twenty-two pre-menopausal evaluable patients with advanced breast cancer (median age 39 years; ER positive 19, unknown three; prior adjuvant chemotherapy 16) were treated with the LHRH agonist goserelin depot (Zoladex*). Serum levels of 17 β-estradiol and progesterone were suppressed by goserelin within 3–4 weeks of therapy, while serum leuteinizing hormone and follicle stimulating hormone titers remained in the low level of the normal range. Complete or partial response was documented in seven… 
Goserelin in Premenopausal Patients with Advanced Breast Cancer—A Multicenter Study
Goserelin was effective in heavily pretreated premenopausal patients with metastatic breast cancer, independent of hormonal receptor status, previous chemotherapy, and possibly, of ovarian suppression degree.
Failure of goserelin ovarian ablation in premenopausal women with breast cancer: two case reports.
Goserelin-induced ovarian ablation may fail after the use of appropriate doses of this drug, and a possible mechanism of hormone resistance induced by the long-term administration of LHRH analogues is suggested.
Pregnancy in a breast cancer patient treated with a LHRH analogue at ablative doses.
A 36-year-old female diagnosed of breast cancer was treated with surgery, chemotherapy, radiotherapy and goserelin. After 17 months of uninterrupted therapy with this LHRH analogue at hormone
LHRH agonist treatment of breast cancer and gynecological malignancies: a review.
Tolerability of hormone therapies for breast cancer: How informative are documented symptom profiles in medical notes for ‘well-tolerated’ treatments?
There was a significant difference in the frequency of many side effects reported by the two methods in this study, and prospective patients cannot make informed judgements on proposed treatments without accurate comprehensive side effect profiles for hormone therapies.
Clinical Pharmacokinetics of Goserelin
Goserelin is extensively metabolised prior to excretion, but its pharmacokinetics are unaffected by hepatic impairment, but the mean t1/2β increases to 12.1 hours in patients with severe renal impairment, which suggests that the total renal clearance is decreased in Patients with renal dysfunction.
Hormonal therapy for breast cancer. An update.
LHRH Superagonists and Antagonists in the Treatment of Breast Cancer
The biology of the luteinizing hormone-releasing hormone (LHRH) analogs is summarized and their role in the clinical management of breast cancer is reviewed critically.
Endocrinology of Breast Cancer
  • A. Manni
  • Medicine
    Contemporary Endocrinology
  • 1999